Bolis Matteo, Uceda Renteria Sara, Alagna Laura, Liparoti Arianna, Passerini Beatrice Zita, Pastena Andrea, Parisi Alessandra, Callegaro Annapaola, Bandera Alessandra, Muscatello Antonio, Alteri Claudia
Infectious Diseases Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy.
Microbiology and Virology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy.
BMC Infect Dis. 2025 Mar 13;25(1):359. doi: 10.1186/s12879-025-10740-w.
Prolonged SARS-CoV-2 infection observed in immunocompromised individuals even in the presence of antiviral treatment provides opportunities for viruses to evolve in immune escape and drug-resistant variants.
A 72-year-old male with IgG4-related disease was admitted to the Emergency Department of a city Hospital in Milan and then transferred to Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in December 2023, due to respiratory distress due to SARS-CoV-2 infection diagnosed in November 2023. After 117 days since the onset of the infection, and two cycles of sotrovimab/remdesivir combined therapy, the clinical improvement allowed the hospital discharge, notwithstanding the persistent SARS-CoV-2 positivity. Fifteen days later, the patient was re-admitted to the hospital due to worsening clinical conditions. After a third cycle of sotrovimab/remdesivir combined therapy prolonged with nirmatrelvir/ritonavir, nasopharyngeal load dropped and clinical conditions improved, ending with a successful discharge. SARS-CoV-2 whole genome sequences, obtained at six time-points of infection, showed an FL.1.5.1 recombinant form infection and a genetic distance of median (IQR) 0.00052 (0.00041-0.00066) similar to the genetic distance observed among the 43 contemporaneous FL.1.5.1 recombinant forms (p = 0.098). De novo SNPs were observed at all time points, with a peak (n = 70) at day 133 of infection, corresponding to the time of the second hospitalization. Six non-synonymous mutations (three in the RdRp and three in the spike protein, four of them known to be associated with drug resistance) appeared transiently, after the third and fourth course of sotrovimab 500 mg/remdesivir combination. Five de novo SNPs, three of them in the spike protein, were fixed over the long-lasting infection. The spike N856K, associated with reduced fusogenicity and infectivity in Omicron BA.1, was completely replaced by constitutive N at day 136.
This clinical case confirms the intra-host evolution dynamics of SARS-CoV-2 in an immunocompromised, prolonged-infected individual, involving positions associated with drug resistance and fusogenic traits of SARS-CoV-2. These results underscore the importance of the early detection of SARS-CoV-2 infection in immunocompromised individuals, and its rapid containment using highly effective treatment, to limit serious complications and the risk of new and potentially concerning viral variants emergence.
即使在接受抗病毒治疗的情况下,免疫功能低下个体中仍观察到严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的长期感染,这为病毒在免疫逃逸和耐药变异体方面的进化提供了机会。
一名72岁的男性,患有IgG4相关疾病,因2023年11月诊断出的SARS-CoV-2感染导致呼吸窘迫,被收入米兰一家城市医院的急诊科,随后于2023年12月转至IRCCS Ca' Granda Ospedale Maggiore Policlinico基金会医院。在感染开始117天后,经过两个周期的索托维单抗/瑞德西韦联合治疗,尽管SARS-CoV-2检测仍呈阳性,但临床症状改善,患者得以出院。15天后,患者因临床症状恶化再次入院。在第三个周期的索托维单抗/瑞德西韦联合治疗并延长使用奈玛特韦/利托那韦后,鼻咽部病毒载量下降,临床症状改善,最终成功出院。在感染的六个时间点获得的SARS-CoV-2全基因组序列显示为FL.1.5.1重组形式感染,中位(四分位间距)遗传距离为0.00052(0.00041 - 0.00066),与43个同期FL.1.5.1重组形式中观察到的遗传距离相似(p = 0.098)。在所有时间点均观察到新发单核苷酸多态性(SNP),在感染第133天出现峰值(n = 70),这与第二次住院时间相符。在索托维单抗500 mg/瑞德西韦联合治疗的第三和第四个疗程后,出现了六个非同义突变(三个在RNA依赖的RNA聚合酶(RdRp)中,三个在刺突蛋白中,其中四个已知与耐药性相关),但为短暂出现。在长期感染过程中,五个新发SNP固定下来,其中三个在刺突蛋白中。在奥密克戎BA.1中与融合性和传染性降低相关的刺突N856K,在第136天被组成型N完全取代。
该临床病例证实了SARS-CoV-2在免疫功能低下、长期感染个体中的宿主内进化动态,涉及与SARS-CoV-2耐药性和融合特性相关的位点。这些结果强调了在免疫功能低下个体中早期检测SARS-CoV-2感染并使用高效治疗迅速控制感染的重要性,以限制严重并发症以及新的、可能令人担忧的病毒变异体出现的风险。